Therapeutics, Inc Share Price: LENZ (Therapeutics, Inc) Stock Price Today & Updates | INDmoney

Question 1

What is Therapeutics, Inc share price today?

Accepted Answer

Therapeutics, Inc (LENZ) share price today is {{live_price}}.

Question 2

Can Indians buy Therapeutics, Inc shares?

Accepted Answer

Yes, Indians can invest in the Therapeutics, Inc (LENZ) from India.

With INDmoney, you can buy Therapeutics, Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Therapeutics, Inc at zero transaction cost.

Question 3

How can I buy Therapeutics, Inc shares from India?

Accepted Answer

It is very easy to buy Therapeutics, Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Therapeutics, Inc be purchased?

Accepted Answer

Yes, you can buy fractional shares of Therapeutics, Inc with INDmoney app.

Question 5

What are the documents required to start investing in Therapeutics, Inc stocks?

Accepted Answer

To start investing in Therapeutics, Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Therapeutics, Inc

Accepted Answer

Today’s highest price of Therapeutics, Inc (LENZ) is {{1_rba_end}}.

Today’s lowest price of Therapeutics, Inc (LENZ) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Therapeutics, Inc

Accepted Answer

Today's market capitalisation of Therapeutics, Inc LENZ is 600.5M

Question 8

What is the 52 Week High and Low Range of Therapeutics, Inc

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Therapeutics, Inc is down from its 52 Week High?

Accepted Answer

Therapeutics, Inc (LENZ) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Therapeutics, Inc is up from its 52 Week low?

Accepted Answer

Therapeutics, Inc (LENZ) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Therapeutics, Inc?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Therapeutics, Inc

Accepted Answer

Mr. Evert B. Schimmelpennink is the current Chief Executive Officer (CEO) of Therapeutics, Inc.

Period	Therapeutics, Inc	Index (Russel 2000)
3 Months	31.03%	0.0%
6 Months	16.26%	0.0%
1 Year	50.93%	0.0%
3 Years	50.93%	-20.8%

Market Capitalization	600.5M
Book Value	$7.46
Dividend Share	0.0
Dividend Yield	0.0%
Earnings Per Share (EPS)	-2.74
Wall Street Target Price	33.8

Profit Margin	0.0%
Operating Margin TTM	0.0%

Return On Assets TTM	-77.17%
Return On Equity TTM	-157.61%

Revenue TTM	0.0
Revenue Per Share TTM	0.0
Quarterly Revenue Growth YOY	0.0%
Gross Profit TTM	0.0
EBITDA	-75.3M
Diluted Eps TTM	-2.74
Quarterly Earnings Growth YOY	0.0

Therapeutics, Inc (LENZ)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Technicals Summary

Peers

Company Information

Discover More

FAQs

EPS Estimate Current Year	-2.81
EPS Estimate Next Year	-2.57
EPS Estimate Current Quarter	-0.48
EPS Estimate Next Quarter	-0.49

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Therapeutics, Inc	2.13%	16.26%	50.93%	50.93%	50.93%
Regeneron Pharmaceuticals, Inc.	-10.93%	8.12%	21.23%	85.29%	239.25%
Novo Nordisk A/s	-9.85%	-6.35%	25.79%	137.8%	353.05%
Alnylam Pharmaceuticals, Inc.	5.73%	77.74%	60.24%	32.45%	248.92%
Vertex Pharmaceuticals Incorporated	-0.6%	17.7%	29.79%	160.59%	174.92%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Therapeutics, Inc	NA	NA	NA	-2.81	-1.58	-0.77	0.0	7.46
Regeneron Pharmaceuticals, Inc.	26.81	26.81	1.38	45.04	0.17	0.08	NA	261.41
Novo Nordisk A/s	39.53	39.53	1.79	3.39	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.47	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.56	0.33	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Therapeutics, Inc	Buy	$600.5M	50.93%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$111.6B	239.25%	26.81	32.04%
Novo Nordisk A/s	Buy	$519.8B	353.05%	39.53	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$34.8B	248.92%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$120.8B	174.92%	32.84	-4.74%

Organization	Therapeutics, Inc
Employees	0
CEO	Mr. Evert B. Schimmelpennink
Industry	Miscellaneous